Zacks Research Issues Negative Outlook for Exelixis Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Zacks Research reduced their Q4 2027 earnings estimates for Exelixis in a research report issued on Tuesday, August 4th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of $1.00 per share for the quarter, down from their prior estimate of $1.02. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.15 per share. Zacks Research also issued estimates for Exelixis’ Q1 2028 earnings at $0.97 EPS and Q2 2028 earnings at $0.99 EPS.

Several other analysts have also issued reports on the company. Citigroup reiterated a “market outperform” rating on shares of Exelixis in a report on Wednesday, July 22nd. UBS Group set a $55.00 target price on Exelixis in a research note on Monday. Stifel Nicolaus upped their target price on Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. HC Wainwright reaffirmed a “buy” rating and set a $56.00 price target on shares of Exelixis in a research note on Thursday, July 2nd. Finally, Morgan Stanley lifted their price target on Exelixis from $50.00 to $53.00 and gave the company an “equal weight” rating in a report on Thursday, July 23rd. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $49.50.

Exelixis Stock Up 1.7%

Exelixis stock opened at $56.00 on Wednesday. The company’s fifty day simple moving average is $53.95 and its 200-day simple moving average is $47.76. Exelixis has a 12 month low of $33.76 and a 12 month high of $57.57. The stock has a market cap of $14.08 billion, a P/E ratio of 18.60, a P/E/G ratio of 1.59 and a beta of 0.44.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm had revenue of $610.81 million for the quarter, compared to analyst estimates of $607.51 million. During the same quarter in the prior year, the business earned $0.55 EPS. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year.

Hedge Funds Weigh In On Exelixis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Motiv8 Investments LLC acquired a new stake in shares of Exelixis in the fourth quarter worth $26,000. Cassaday & Co Wealth Management LLC acquired a new position in Exelixis in the 1st quarter valued at $27,000. Western Wealth Management LLC acquired a new position in Exelixis in the 1st quarter valued at $29,000. Acumen Wealth Advisors LLC bought a new position in Exelixis in the 4th quarter worth $29,000. Finally, Activest Wealth Management bought a new position in Exelixis in the 4th quarter worth $32,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In related news, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the completion of the sale, the chief financial officer directly owned 952,317 shares in the company, valued at approximately $47,615,850. This represents a 3.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Sue Gail Eckhardt sold 9,812 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $50.14, for a total transaction of $491,973.68. Following the transaction, the director directly owned 16,079 shares in the company, valued at $806,201.06. The trade was a 37.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 219,170 shares of company stock valued at $10,620,641 in the last three months. 2.60% of the stock is currently owned by company insiders.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.